[ad_1]
Late last week, the U.S. Food and Drug Administration gave accelerated approval to the Alzheimer’s drug lecanemab, developed by Eisai Co. and Biogen Inc. The drug will be sold under the brand Leqembi and will run about $26,500 for a…
[ad_2]
Source link
